Tislelizumab with platinum-doublet chemotherapy followed by hypofractionated radiotherapy for stage IIIB/C–IV non-squamous NSCLC

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-arm phase II trial giving Tislelizumab together with platinum-based doublet chemotherapy, followed by hypofractionated radiotherapy and continued Tislelizumab. The study will track tumor response and safety outcomes in patients with stage IIIB/C–IV non-squamous NSCLC and ECOG performance status 0–2. Key exclusions include known driver mutations (EGFR, ALK, ROS1, RET, BRAF, MET), uncontrolled autoimmune disease, prior systemic therapy, and pregnancy or lactation. All treatments and follow-up are conducted at a single center in Zibo, Shandong.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18-75 years old, gender is not limited;
2. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
3. Patients with stage IIIB/C-IV non-squamous non-small cell lung cancer confirmed by cytology or histology;
4. Patients who have not received prior systemic therapy;

Exclusion Criteria:

1. Patients with uncontrolled autoimmune diseases;
2. Patients who have had autoimmune reactions in the past 6 months and have not improved or are unstable despite appropriate treatment, such as untreated or unstable pneumonia, thyroiditis, myocarditis, etc.;
3. Patients known to carry driver gene mutations such as EGFR mutation, ALK translocation, BRAF, ROS1, RET, MET, etc.;
4. Patients who have received prior systemic therapy, or those who have received adjuvant or neoadjuvant therapy with a recurrence time of less than 3 months from the last treatment;
5. Patients with known allergies or contraindications to the study drug or its excipients;
6. Pregnant or lactating female patients, or female patients of childbearing potential with a positive baseline pregnancy test;
7. Female patients of childbearing potential or male patients with reproductive plans who are unwilling to use effective contraception during the entire trial period and for 6 months after the end of the trial;
8. Patients whose comorbidities or other conditions may affect compliance with the protocol or are deemed unsuitable for participation in this study by the investigator.

Where it's running

• Zibo Municipal Hospital
  Zibo, Shandong, China Recruiting

Study contacts

• Study coordinator: Qiang Wang
• Email: 18953316759@163.com
• Phone: +8618953316759

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Platinum-doublet chemotherapy followed by large-fraction radiotherapy with tislelizumab for advanced non-squamous NSCLC

  We will try platinum-based doublet chemotherapy followed by large-fraction radiotherapy together with tislelizumab in people with stage IIIB/C–IV non-squamous non-small cell lung cancer who cannot tolerate concurrent chemoradiotherapy.

  Recruiting Phase 2 Zibo Municipal Hospital · Zibo, Shandong · NCT07198217

• Intestinal Low-Dose Radiotherapy plus Immunochemotherapy to Convert Borderline Resectable or Unresectable Esophageal Squamous Cell Carcinoma

  This study tests whether adding a very low dose intestinal radiotherapy with immunochemotherapy can make advanced esophageal squamous cell carcinoma operable for patients who can’t be surgically removed today.

  Recruiting Phase 2 Shantou University Medical College · Shantou, Guangdong · NCT07339488

• Tislelizumab with Anlotinib and Nab-Paclitaxel before surgery for resectable NSCLC

  A group of adults with stage II–III non-small cell lung cancer is given tislelizumab plus anlotinib and nab-paclitaxel before surgery to see if the treatment helps shrink tumors and is safe.

  Recruiting Phase 2 Qilu Hospital of Shandong University · Jinan, Shandong · NCT07089199

• Adding tislelizumab with or without the probiotic Probio-M9 to pre-surgery chemoradiation for pMMR/MSS locally advanced rectal cancer.

  This will see if adding the PD-1 drug tislelizumab, with or without the probiotic Probio-M9, to standard pre-surgery chemoradiation helps adults with pMMR/MSS locally advanced rectal cancer.

  Recruiting Phase 2 Seventh Medical Center of PLA General Hospital · Beijing, Beijing Municipality · NCT07458529

• Adjuvant L-TIL plus tislelizumab after surgery for resectable NSCLC without pCR

  This trial tests whether giving liquid tumor-infiltrating lymphocytes (L-TIL) together with the PD-1 blocker tislelizumab after surgery helps people with resectable stage II–IIIB NSCLC who did not achieve a complete response to pre-surgery chemoimmunotherapy.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07330037

• Nephron-sparing tislelizumab and nab-paclitaxel for renal pelvic cancer

  This study will try combining tislelizumab and nab‑paclitaxel to shrink HER‑2–expressing renal pelvic tumors in adults eligible for ureteroscopic laser ablation.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin, Outside U.S. · NCT07233252

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.